Whereas highly penetrant variants have proven well-suited to human induced 40 pluripotent stem cell (hiPSC)-based models, the power of hiPSC-based studies 41 to resolve the much smaller effects of common variants within the size of cohorts 42 that can be realistically assembled remains uncertain. In developing a large 43 case/control schizophrenia (SZ) hiPSC-derived cohort of neural progenitor cells 44 and neurons, we identified and accounted for a variety of technical and biological 45 sources of variation. Reducing the stochastic effects of the differentiation process 46 by correcting for cell type composition boosted the SZ signal in hiPSC-based 47 52 cohorts currently feasible, in most cases and whenever possible, we recommend 53 expanding the number of individuals even at the expense of the number of 54 replicate hiPSC clones. 55 56 ABBREVIATIONS 57 58 schizophrenia, SZ; childhood onset schizophrenia, COS; human induced 59 pluripotent stem cell, hiPSC; neural progenitor cell, NPC; genome wide 60 association study, GWAS; copy number variation, CNV; single nucleotide 61 polymorphism, SNP; expression quantitative trait loci, eQTL.
models and increased the concordance with post mortem datasets. Because this 48 concordance was strongest in hiPSC-neurons, it suggests that this cell type may 49 better model genetic risk for SZ. We predict a growing convergence between 50 hiPSC and post mortem studies as both approaches expand to larger cohort 51 sizes. For studies of complex genetic disorders, to maximize the power of hiPSC INTRODUCTION 6 respective hiPSC-NPCs and hiPSC-neurons. In total, 76 samples (81%; n=38 201 hiPSC-NPC, n=38 hiPSC-neurons; n=36 COS, n=40 controls, from 10 unique 202 COS and 9 unique control individuals) were validated for subsequent analysis 203 (Table 1; SI Table 2 ; SI Fig. 3B ). 204 205 Residual Sendai virus expression was assessed using Inchworm in the Trinity 206 package 45 , which performed de novo assembly of reads that did not map to the 207 human genome. Comparisons of these contigs to the Sendai virus genome 208 sequence (GenBank: AB855655.1) quantified the number of reads corresponding 209 to residual Sendai expression in each NPC and neuron sample. Although Sendai 210 viral vectors are widely assumed to be lost within eleven hiPSC passages 46 , and 211 that on average our hiPSCs were passaged >10-15 times and our hiPSC-NPCs 212 >5 times, we identified Sendai viral transcripts in a subset of our samples. While 213 the majority (70 of 87, 80%) (75 of the total 94, 79.8%) of RNA-Seq samples did 214 not contain any reads that mapped to the Sendai viral genome, 17 (or 19 of total) 215 samples (SI Table 2 ; SI Fig. 4 ) showed evidence of persistent Sendai viral 216 expression at > 1 count per million. Differential expression analysis identified 217 2768 genes correlated with Sendai expression at FDR < 5% (SI Table 5 ). We 218 note that this signal is not driven by outliers since quantile normalized Sendai 219 expression values were used in this analysis. In fact, these genes are highly 220 enriched for targets of MYC (OR = 3.75, p < 6.4e-38) (SI Table 6 , SI Fig. 5A) . 221 Although MYC is one of the four transcription factors (along with SOX2, KLF4, 222 and OCT4) used in hiPSC reprogramming, expression of these four genes was 223 not associated with Sendai expression (SI Fig. 5B ). The correlation of residual 224 Sendai expression with activation of MYC targets suggests that this could be a Overall, our rigorous bioinformatic strategy adjusted for technical variation and 231 batch effects, eliminated spurious samples, and flagged samples that were 232 contaminated or had aberrant X-inactivation. This extensive analysis was 233 motivated by the high level of intra-donor expression variation (see below), and 234 eliminating these factors as possible explanations for this expression variation 235 ultimately improved our ability to resolve SZ-relevant biology in our dataset.
237
COS hiPSC-NPC and hiPSC-neuron RNA-Seq data cluster with existing hiPSC 238 and post mortem brain datasets 239 240 To assess the similarity of our hiPSC-NPCs and hiPSC-neurons to other hiPSC 241 studies (by ourselves and others), as well as to post mortem brain, we compared 242 our dataset to publically available hiPSC, hiPSC-derived NPCs/neurons, and 243 post mortem brain homogenate expression data sets (Fig. 2) . Hierarchical 244 clustering indicated that similarity in expression profiles is largely determined by 245 cell type ( Fig. 2A) . hiPSC-NPC and hiPSC-neuron datasets were more similar to 246 7 prenatal samples than postnatal or adult post mortem samples [47] [48] [49] , which is 247 consistent with previous reports 13, [21] [22] [23] [24] . hiPSC-NPCs and hiPSC-neurons, as well 248 as post mortem brain samples, cluster separately from hiPSCs, ESCs, fibroblasts 249 and whole blood 35, 47, 50 . Despite being reprogrammed and differentiated through 250 different methodologies, hiPSC-NPCs and hiPSC-neurons from the current study 251 cluster with hiPSC-NPCs and hiPSC-neurons, respectively, generated previously 252 in the same lab 10,12 and with hiPSC-NPCs and hiPSC-neurons from others 14 , 253 although some hiPSC-neurons 19 are more similar to prenatal brain samples from 254 multiple brain regions 49 . Consistent with a differentiation paradigm from hiPSC 255 to NPC to neuron, multidimensional scaling analysis ( Fig. 2B) indicated that 256 hiPSC-NPCs more resemble hiPSCs / hESCs than do hiPSC-neurons.
258
Genome-wide, hiPSC-NPCs and hiPSC-neurons express a common set of 259 genes, so that expression differences between these cell types are driven by 260 changes in expression magnitude rather than activation of entirely different 261 transcriptional modules (SI Fig. 6 ). Moreover, for both hiPSC-NPCs and hiPSC-262 neurons, genes that show high variance across donors in each cell type are 263 enriched for brain eQTLs (SI Fig. 7) . Taken together, these two insights justified 264 case-control comparisons within and between both hiPSC-NPCs and hiPSC-265 neurons.
267
Large heterogeneity in cell type composition in both NPCs and hiPSC-neurons 269 270 Given the substantial variability we observed between hiPSC-NPCs and hiPSC- neurons, but also inhibitory and rare dopaminergic neurons, as well as astrocytes 277 11 . We hypothesized that CTC could be inferred using existing single cell RNA-
278
Seq datasets and would enable us to (partially) correct for variation in 279 differentiation efficiencies and account for some of the intra-individual expression 280 variation.
282
Bulk RNA-Seq analysis reflects multiple constituent cell types; therefore, we 283 performed computational deconvolution analysis using CIBERSORT 51 to 284 estimate CTC scores for each hiPSC-NPC and hiPSC-neuron sample (Fig. 3) . 285 A reference panel of single cell sequencing data from mouse brain 52 , mouse cell 286 culture of single neural cells 53 and bulk RNA-Seq from hiPSC 50 was applied.
288
Overlaying CTC scores on a principal component analysis (PCA) of the 289 expression data indicates that hiPSC-NPCs and hiPSC-neurons separate along 290 the first principal component (PC), explaining 37.6% of the variance, and that the 291 cell types have distinct CTC scores ( Fig. 3A-C) . As expected, hiPSC-neuron 292 8 samples had a higher neuron CTC score than hiPSC-NPCs ( Fig. 3A) , while 293 hiPSC-NPCs had a higher hiPSC CTC score, consistent with a "stemness" signal 294 (a neural stem cell profile was lacking from our reference) ( Fig. 3B) . 295 Unexpectedly, hiPSC-NPCs had a higher fibroblast 1 score ( Fig. 3C) . Rather than 296 imply that there are functional fibroblasts within the hiPSC-NPC populations, we 297 instead posit that this fibroblast signature is instead marking a subset of 298 unpatterned, potentially non-neuronal cells 53 . Analysis of external NPC and 299 neuron datasets indicates that these observations were reproducible, although 300 there is substantial variability in CTC scores across datasets (SI Fig. 9 ). 301 Although correction for CTC improved our ability to distinguish hiPSC-NPC and 302 hiPSC-neuron populations, nonetheless, there remained substantial variability 303 within both the hiPSC-NPCs and hiPSC-neurons that corresponded to CTC ( Fig.   304 3D).
306
The effect of CTC heterogeneity, likely due to the variation in differentiation 307 efficiency, can be reduced by including multiple CTC scores in a regression 308 model and computing the residuals.
Using an unbiased strategy, we 309 systematically evaluated which CTC score(s), when included in our model, most 310 explained the variance in our samples. PCA on the residuals from a model 311 including fibroblast 1 and fibroblast 2 CTC scores showed a markedly greater 312 distinction between cell types, such that the first PC now explained 45.3% of the 313 variance ( Fig. 3E) . Moreover, accounting for the CTC scores increased the 314 similarity between the multiple biological replicates generated from the same 315 donor and resulted in less intra-individual variation within each cell type ( Fig. 3F , 316 SI Fig. 10 ). Finally, accounting for CTC was necessary in order to see 317 concordance with one of the adult post mortem cohorts (see below).
319
Characterizing known sources of expression variation in COS and control NPC 320 and neuron RNA-Seq dataset 321 322
As discussed above, gene expression (in our dataset and others) is impacted by 323 a number of biological and technical factors. By properly attributing multiple 324 sources of expression variation, it is possible to (partially) correct for some 325 variables. To decompose gene expression into the percentage attributable to 326 multiple biological and technical sources of variation, we applied 327 variancePartition 54 (Fig. 4) . For each gene we calculated the percentage of 328 expression variation attributable to cell type, donor, diagnosis, sex, as well as 329 CTC scores for both fibroblast sets. All remaining expression variation not 330 attributable to these factors was termed residual variation. The influence of each 331 factor varies widely across genes; while expression variation in some genes is 332 attributable to cell type, other genes are affected by multiple factors (Fig. 4A) . 333 Overall, and consistent with the separation of hiPSC-NPCs and hiPSC-neurons 334 by the first PC, cell type has the largest genome-wide effect and explained a 335 median of 13.3% of the observed expression variation (Fig. 4B) Critically, there is no apparent diagnosis dependent variation in CTC (SI Fig. 12 ).
354
By compensating for CTC, we prevent variation in neuronal differentiation 355 between hiPSCs from overriding some of the donor-specific gene expression 356 signature that is the central focus of patient-derived cell culture models.
358
The percentage of expression variation explained by each factor has a specific 359 biological interpretation. PRRX1 is known to function in fibroblasts 56,57 and 360 variation in the fibroblast 1 CTC score explains 38.3% of expression variant in this 361 gene ( Fig. 4C) . Expression of CNTC4 is driven by an eQTL in brain tissue that 362 corresponds a risk locus for schizophrenia 48 . In our data, CNTC4 has 67.4% 363 expression variation across donors suggesting that this variation is driven by 364 genetics (Fig. 4D) . Genes that vary across diagnosis correspond to differentially 365 expressed genes, including FZD6, a WNT signaling gene linked to depression 58 , 366 ( Fig. 4E) and QPCT, a pituitary glutaminyl-peptide cyclotransferase that has 367 been previously associated with SZ 59 (Fig. 4F) .
369
Genes that vary across donors were enriched for eQTLs detected in post mortem 370 brain tissue 48 (Fig. 4G) Genes with similar functions are known to share regulatory mechanisms and so 383 are often coexpressed 60 . We used weighted gene coexpression network 384 10 analysis (WGCNA) 61 to identify modules of genes with shared expression 385 patterns ( Fig. 5 , SI Table 7) . Genes were clustered into modules of a minimum 386 of 20 genes, and each module was labeled with a color (SI Fig. 13 Differential expression analysis between cases and controls in hiPSC-NPCs ( Fig.   420 6A) identified 1 gene with FDR < 10% and 5 genes with FDR < 30%; analysis in 421 hiPSC-neurons ( Fig. 6B ) identified 1 gene with FDR < 10% and 5 genes with 422 FDR < 30% (SI Table 8 ).
424
While plausible candidates such as FZD6 and QPCT were differentially 425 expressed, gene set enrichment testing did not implicate a coherent set of 426 pathways (SI Table 9 ). Since SZ is a highly polygenic disease 67,68 and this 427 dataset is underpowered due to the small sample size 48 , we expected the 428 disease signal to be subtle and distributed across many genes. Despite 429 performing extensive analysis using sophisticated statistical methods 69-71 built on 430 11 top of the limma/voom framework 63 that incorporated genes that were not 431 genome-wide significant and using permutations to empirically set the 432 significance cutoff (see Methods), we failed to identify a coherent biological 433 enrichment. Nonetheless, there was an unexpected concordance in the 434 differential expression analysis between COS and control hiPSC-NPCs and 435 hiPSC-neurons, which showed remarkably similar log 2 fold changes (Fig. 6C) . 436 Moreover, no genes had log 2 fold changes that were statistically different in the 437 two cell types, although we were underpowered to detect such differences.
439
Overall, our differential expression analysis demonstrated that case-control The Spearman correlation between our hiPSC-NPC results and the CMC and 461 HBCC results were 0.108 and 0.0661, respectively; for the hiPSC-neurons 462 results, the correlations were 0.134 and 0.0896, respectively (Fig. 6D, SI Fig. 14-463 15). These correlations were highly statistically significant (Fig. 6E) Fig. 14-15 ). This stronger concordance of hiPSC-neurons (relative to hiPSC-469 NPCs) with post mortem findings is consistent with the hypothesis that neurons 470 are the cell type most relevant to SZ risk 72 , but our ability to resolve it is perhaps 471 surprising in that neurons are estimated to comprise a minority of the cells in 472 brain homogenate 73 .
474
While the concordance with CMC was observed when correcting for any set of 475 CTC scores (or none), the concordance with HBCC was only apparent when 476 correcting for the fibroblast 1 CTC score (SI Fig. 16 ). This illustrates the 477 importance of accounting for CTC and the fact that concordance can be 478 obscured by biological sources of expression variation. The genes for which the 479 differential expression signal was boosted by accounting for the fibroblast 1 score 480 were enriched for brain and synaptic genesets, including specific biological 481 functions such as FMRP and mGluR5 targets (SI Fig. 17,18) .
483
This result indicates that although the concordance between hiPSC-NPCs and 484 hiPSC-neurons with two post mortem datasets is relatively low due to the small 485 sample size and low power of our current study, the concordance of the 486 biological findings will increase with increasing sample size in future studies. Given the challenges of low statistical power, substantial intra-donor variation, (Fig. 7) . When the cost for each donor and each additional replicate are 545 equal, adding an additional donor will increase the ESS by one unit (Fig. 7A) , 546 while adding an additional sample from an existing donor will increase the ESS larger increase on ESS. The fact that the donor effect in the current study is 553 lower than in previous hiPSC studies 35, 55 affects the contribution of each 554 additional sample to the ESS (Fig. 7B) . When the costs for an additional hiPSC 555 line are less than the cost of an additional donor, the calculus changes in favor of 556 including additional biological replicates (Fig. 7C,D) . We have developed a 557 public website (http://gabrielhoffman.shinyapps.io/design_ips_study/) that 558 computes the ESS in order to design a study to maximize power. These 559 calculations consider constraints on either total budget or number of donors, as 560 the relative cost and donor effect change. Overall, our conclusion is that the best 561 way to maximize ESS, while controlling the false positive rate, is often to use one 562 hiPSC line per donor and increase the number of donors, rather than using 563 multiple replicate clones from a smaller set of donors 42, 65, 66 .
565
In addition to maximizing cohort ESS, future studies will benefit from decreasing 566 intra-donor expression variation by optimizing neuronal differentiation/induction 567 protocols to focus on decreasing cellular heterogeneity (rather than increasing 568 14 total yield). 
